CN109893557B - Traditional Chinese medicine composition for treating sequelae of pelvic inflammatory disease - Google Patents
Traditional Chinese medicine composition for treating sequelae of pelvic inflammatory disease Download PDFInfo
- Publication number
- CN109893557B CN109893557B CN201910248021.8A CN201910248021A CN109893557B CN 109893557 B CN109893557 B CN 109893557B CN 201910248021 A CN201910248021 A CN 201910248021A CN 109893557 B CN109893557 B CN 109893557B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- pelvic inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for treating sequelae of pelvic inflammatory diseases, which comprises the following active ingredients in parts by weight: 10-14 parts of ground beetle; 10-14 parts of radix angelicae pubescentis; 10-14 parts of szechwan chinaberry fruit; 13-17 parts of paniculate swallowwort root. The invention further provides application of the traditional Chinese medicine composition, the traditional Chinese medicine extract or the medicinal preparation in preparing a medicament for treating sequelae of pelvic inflammatory diseases. The invention provides a traditional Chinese medicine composition for treating sequelae of pelvic inflammatory diseases, which has good effects of analgesia, blood circulation promotion, anti-inflammation and the like through the synergistic effect of preferred components, and can play a role in eliminating dampness and stasis and treating Kunzenning.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating sequelae of pelvic inflammatory diseases.
Background
The sequelae of the pelvic inflammatory disease mainly show chronic pelvic pain and reverse recurrence of the pelvic inflammatory disease, and local and general symptoms such as repeated lower abdominal or lumbosacral pain, abnormal leucorrhea, abdominal masses, menstrual disorder, low fever, easy fatigue and the like appear, and are mostly developed for women of childbearing age. The main pathological manifestations of the pelvic inflammatory sequelae are tissue damage, extensive adhesion, hyperplasia and scar formation, thereby causing the blockage of the fallopian tube, forming a mass, the locking of the umbrella end of the fallopian tube and hydroscopic water of the fallopian tube, and further causing infertility and ectopic pregnancy. The disease is difficult to cure quickly and easy to recur, and the treatment is always a clinical difficulty, which seriously affects the physical and mental health of women, the daily work and the quality of life.
Regarding this disease, modern medicine has no effective treatment means. Antibiotics have definite curative effect on clearing pathogens in the acute stage, but benefit little on improving clinical symptoms and repairing injuries in the chronic stage; the surgical treatment mainly comprises the steps of removing focus and performing adhesion loosening operation on a patient with severe adhesion of the pelvic cavity and the abdominal cavity so as to relieve pelvic pain, but the curative effect is not satisfactory. Under the background, the advantages of the traditional Chinese medicine for treating the disease are gradually highlighted. Therefore, there is a need to find therapeutic formulations with superior efficacy from a traditional chinese medicine perspective.
Disclosure of Invention
In view of the disadvantages of the prior art, the present invention aims to provide a traditional Chinese medicine composition for treating sequelae of pelvic inflammatory diseases, which is used for solving the problem that the traditional Chinese medicine composition for treating sequelae of pelvic inflammatory diseases with analgesic, blood circulation promoting and anti-inflammatory effects is lacked in the prior art.
In order to achieve the above and other related objects, a first aspect of the present invention provides a Chinese medicinal composition, which comprises the following components in parts by weight:
10-14 parts of ground beetle (Eupolyphga Sinensis Walker);
10-14 parts of pubescent angelica root (Heracleum hemsleyanum Diels);
10-14 parts of Fructus Toosendan (Fructus Toosendan);
13-17 parts of paniculate swallowwort root (Cynanchum paniculatum (Bunge) Kitagawa).
Preferably, the traditional Chinese medicine composition comprises the following active ingredients in parts by weight:
11-13 parts of Chinese polyphaga;
11-13 parts of pubescent angelica root;
11-13 parts of szechwan chinaberry fruit;
14-16 parts of paniculate swallowwort root.
Preferably, the traditional Chinese medicine composition comprises the following active ingredients in parts by weight:
12 parts of Chinese polyphaga;
12 parts of pubescent angelica root;
12 parts of szechwan chinaberry fruit;
15 parts of paniculate swallowwort root.
The traditional Chinese medicine composition is characterized in that the repeated attacks of pelvic pain are taken as main symptoms according to sequelae of pelvic inflammatory diseases, and qi and blood stagnation is bound in the pain part by the theory of 'pain obstruction' in traditional Chinese medicine; the pain in the pelvic cavity belongs to the eight diagrams, the female position; the pelvic cavity is in the lower part of the human body and belongs to the yin position, while dampness is yin pathogen and is easy to attack the yin position, and the clinical symptoms of leukorrhagia and lingering pain are consistent with dampness and viscosity. In addition, abnormal leucorrhea and anal pendant distention are the location of the liver meridian, which indicates that the qi movement of the liver meridian is not smooth and that the cold-warm syndrome is complicated. Therefore, the mutual accumulation of dampness and blood stasis, the liver meridian obstruction, the adherence of healthy qi and pathogenic factors, and the intermingled cold and warm are considered as the core of the pathogenesis. Accordingly, the traditional Chinese medicine composition (namely the blood stasis removing and female calming prescription) is created to treat the disease by adopting a method of expelling dampness and dredging collaterals and regulating cold and temperature.
The invention provides a traditional Chinese medicine extract which is prepared from the traditional Chinese medicine composition.
The third aspect of the invention provides a preparation method of a traditional Chinese medicine extract, which comprises the steps of mixing the components according to the proportion, adding a solvent for soaking, then decocting, and reserving filtered liquid medicine for obtaining the traditional Chinese medicine extract.
The above components are all selected from the above medicines and processed.
Preferably, the solvent is water.
Preferably, the ratio of the added mass (g) of the traditional Chinese medicine composition to the added volume (mL) of the solvent is 43-59: 250-350.
More preferably, the ratio of the added mass (g) of the traditional Chinese medicine composition to the added volume (mL) of the solvent is 47-55: 280-320.
Most preferably, the ratio of the mass (g) of the added traditional Chinese medicine composition to the volume (mL) of the added solvent is 51: 300.
Preferably, the soaking time is 25-35 min. More preferably, the soaking time is 30 min.
Preferably, the decoction is continued after boiling.
More preferably, the boiling temperature is 95-105 ℃. Further preferably, the boiling temperature is 100 ℃.
More preferably, the decocting time is 20-30 min. Further preferably, the decocting time is 25 min.
The fourth aspect of the invention provides a pharmaceutical preparation, which comprises the traditional Chinese medicine composition and/or the traditional Chinese medicine extract.
Preferably, the pharmaceutical preparation is selected from one of granules or oral liquid.
The fifth aspect of the invention provides application of the traditional Chinese medicine composition, the traditional Chinese medicine extract or the pharmaceutical preparation in preparing medicines for treating sequelae of pelvic inflammatory diseases.
Preferably, the sequelae of the pelvic inflammatory disease mainly show chronic pelvic pain and reverse recurrence of the pelvic inflammatory disease, and local and systemic symptoms such as repeated lower abdominal or lumbosacral pain, abnormal leucorrhea, abdominal mass, menstrual disorder, low fever, easy fatigue and the like appear, and are mostly developed for women of childbearing age.
As mentioned above, the traditional Chinese medicine composition for treating sequelae of pelvic inflammatory diseases provided by the invention takes the blood stasis removing decoction from the Jinkui Yao L ü e, the Jinlingzi san from the Huo Fa Ji Yao and the Duhuo decoction from the Huo Yan Zi Xin Shu to achieve the effects of promoting blood circulation, dredging collaterals, eliminating dampness and relieving pain. Wherein, the ground beetle has salty and cold nature, enters the blood system of liver channel, has good nature and flees, and can break blood and dispel stasis to eliminate stagnation and blood stasis below the meridians and remove obstruction in the abdomen. Chuan Lian Zi is bitter in flavor and cold in nature, and enters liver, small intestine and bladder channels, purges liver and moves qi to regulate qi stagnation and relieve arthralgia. The pubescent angelica root, pungent and bitter with slight warm property, enters kidney and bladder channels, dispels wind and dampness, and relieves arthralgia and pain. The paniculate swallowwort root, pungent in flavor and warm in nature, which enters liver and stomach meridians, is an ancient Chinese medicine, listed as the superior product in Benjing, and mainly treats ghost, Baijing, poison, epidemic disease, evil and evil, and warm malaria. It can be taken for a long time to strengthen the body. The paniculate swallowwort root has the functions of expelling wind and clearing away cold, removing dampness and relieving pain, detoxifying and reducing swelling, warming and activating meridians and is used for treating various pains caused by rheumatism, congealing cold, qi stagnation and blood stasis with half the effort. The traditional Chinese medicine composition has good effects of easing pain, promoting blood circulation, resisting inflammation and the like on modern pharmacology, and has the effects of dissolving dampness and stasis and calming the female (pelvic cavity) through the synergistic effect of the components.
Drawings
FIG. 1 shows schematic views 1A, 1B, 1C, 1D of inflammatory cell status in uterus and fallopian tubes, wherein 1A is a microscopic view of inflammatory cells in uterus; 1B is a microscopic view of inflammatory cells in the fallopian tube; 1C is a bar graph of inflammatory cell changes in the uterus; 1D is a bar graph of inflammatory cell changes in the fallopian tubes.
FIG. 2 shows graphs 2A, 2B, 2C, 2D showing the change in inflammatory response in ELISA assay for rat serum IL-1 β, TNF- α, ICAM-1 and VEGF levels, where 2A is rat serum IL-1 β; 2B is rat serum TNF-alpha; 2C is rat serum ICAM-1; 2D is rat serum VEGF.
FIG. 3 is a graph showing the change of the staining rate of ICAM-1 in rat serum in uterus and oviduct in FIGS. 3A, 3B, 3C, and 3D, wherein 3A is a microscopic view of the staining rate of ICAM-1 in rat serum in uterus; 3B is a microscopic view of the staining rate of rat serum ICAM-1 in the oviduct; 3C is a column-type curve chart of the change of the staining rate of the rat serum ICAM-1 in the uterus; 3D is a column graph showing the change in the staining rate of ICAM-1 in rat serum in the oviduct.
FIG. 4 is a graph showing the changes in serum VEGF levels in rats in the uterus and oviducts in FIGS. 4A, 4B, 4C, 4D, wherein 4A is a microscopic view of the serum VEGF levels in rats in the uterus; 4B is a microscopic view of rat serum VEGF levels in the oviduct; 4C is a curve chart of the change column of the VEGF level of the rat serum in the uterus; 4D is a plot of the change in serum VEGF levels in the oviduct of rats.
In fig. 1, 3 and 4, the control is a sham-operated blank control group, the PID is a model blank control group, the FKQJ is a model gynecological Qianjin tablet treatment group, the XYNK is a model traditional Chinese medicine composition treatment group of the present invention, and the CP is a model paniculate swallowwort root treatment group.
Detailed Description
The present invention is further illustrated below with reference to specific examples, which are intended to be illustrative only and not to limit the scope of the invention.
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.
The compatibility of the invention accords with the principle of 'monarch, minister, assistant and guide' of the traditional Chinese medicine, the invention adopts the following traditional Chinese medicines which are compatible with each other, can play the role of the synergistic treatment of the traditional Chinese medicines, and the components of the used traditional Chinese medicine raw materials have the efficacy of mutual interweaving, mutual promotion and coordination.
The raw material medicines (or medicinal materials) adopted by the invention can be purchased from common pharmaceutical shops or Chinese medicinal material selling companies, and the specification of the raw material medicines (or medicinal materials) accords with the national pharmaceutical standard or the relevant regulations of Chinese pharmacopoeia and the like. The adopted medicinal materials are Chinese medicinal decoction pieces unless otherwise specified, and the Chinese medicinal decoction pieces can also be obtained and processed.
The term "patient" as used herein refers to humans, wild animals and livestock suffering from a disease. The wild animal is an animal which is not artificially domesticated in a natural state. Livestock are animals that are artificially raised to provide a food source, such as monkeys, apes, dogs, rats, hamsters, pigs, rabbits, horses, cows, buffalos, bulls, sheep, and goats, and the like. The "patient" to be administered the diagnosis is preferably a mammal, especially a human.
The curative effect standard of the invention refers to the relevant curative effect standard in the 'Chinese medicine disease judgment curative effect standard'. And (3) healing: clinical symptoms all disappeared and the laboratory check was normal. Improvement: clinical symptoms were reduced, laboratory examinations were improved or normal. And (4) invalidation: the clinical symptoms are not obviously improved or aggravated.
The preparation process of the invention uses the technical requirements of the research on the preparation process of new traditional Chinese medicines in principle, uses the new technology of modern preparations to extract the main effective components of the medicines for use as the medicine, and adds some pharmaceutically acceptable auxiliary materials or carriers
Example 1
Mixing Eupolyphaga Seu Steleophaga 12g, radix Angelicae Pubescentis 12g, fructus Toosendan 12g, and radix Cynanchi Paniculati 15g, adding 300mL water, decocting for 30min, filtering to obtain 100mL medicinal liquid, and collecting sample of the desired Chinese medicinal composition # 1.
Example 2
Respectively taking 11g of Chinese polyphaga, 11g of radix angelicae pubescentis, 11g of szechwan chinaberry fruit and 14g of paniculate swallowwort root, mixing, adding 280mL of water, decocting for 25 minutes, and filtering to obtain 100mL of liquid medicine to obtain the required Chinese medicinal composition sample No. 2.
Example 3
Mixing Eupolyphaga Seu Steleophaga 13g, radix Angelicae Pubescentis 13g, fructus Toosendan 13g, and radix Cynanchi Paniculati 16g, adding 320mL water, decocting for 35min, filtering to obtain 100mL medicinal liquid, and obtaining the desired Chinese medicinal composition sample # 3.
Example 4
For patients with chronic pelvic inflammatory diseases, the traditional Chinese medicine composition sample 1# obtained in example 1 is taken warm twice in the morning and at night. Meanwhile, the traditional Chinese medicine composition prepared according to the proportion in the embodiment 1 is mixed, mixed with water of 40 ℃ to form paste after 7 days after menstruation is clear, the paste is spread on mulberry white paper, then the mulberry white paper is placed on the Zhongji point, a warm moxibustion box is placed on the mulberry white paper, and the warm moxibustion is continuously carried out for 30min for 1 time/d until the menstruation stops.
In clinical practice, after the traditional Chinese medicine composition is used for treating patients with chronic pelvic inflammatory diseases, clinical symptoms of the patients are improved to different degrees after the patients are treated for 4-8 weeks by the formula, and after the patients are treated by acupuncture point moxibustion, more than half of the patients do not have attack after follow-up for half a year or 1 year, which shows that the formula has better long-term curative effect except the short-term analgesic, blood circulation promoting and anti-inflammatory effects. The patients with the chronic pelvic inflammatory disease are inefficiently referral after treatments of western medicine analgesia, hormone and the like when the patients are 30-50 years old.
The therapeutic principle of the warm moxibustion of the Zhongji point is as follows: zhongji acupoint, 4 cun below the umbilicus, is located at the midline of the lower abdomen and is responsible for various diseases of the pelvic cavity. The point belongs to the meridian point of the ren channel, and is the intersection point of the three yin channels of the foot and the ren channel, and converges qi and blood of four meridians of the liver, spleen, kidney and the ren channel. If the medicine is supplemented with blood stasis removing and female calming prescription, warm moxibustion and skin penetration can further dispel wind and dampness, promote qi and blood circulation, warm and dredge channels and collaterals, and the qi and blood circulation can circulate along the channels without stasis. From the perspective of modern medicine, the therapy can give full play to the local penetrating force, and especially heating the medicine to about 40 deg.C can accelerate local blood circulation, promote softening of hyperplasia fibrous tissue, and facilitate dissipation and absorption of inflammation focus.
Comparative example 1
The pain-relieving and illness-eliminating capsules are taken orally by patients with chronic pelvic inflammatory diseases for 6 times a day and 2 times a day; the medium pole point moxibustion is used for adjuvant treatment.
The comparison of the two shows that the clinical symptoms of patients treated by the traditional Chinese medicine composition are improved to different degrees after the treatment of the formula for 4-8 weeks, and more than half of cases do not attack after the follow-up for half a year or 1 year, and the symptoms are significantly different from those of a control group (the symptom score is classified as shown in table 1, and the symptom score changes before and after two groups of treatment are shown in table 2), which indicates that the formula has better long-term curative effect besides the recent analgesic and blood activating effects.
Example 5
60 patients with pelvic inflammatory disease of wet and stasis interlinked type in 2015 1-2017 and 12 were selected, and the study was performed in parallel with the gynecological climbing fern tablets (control group, 1 time 6 tablets, 1 day 3 times) (1:1) by using the traditional Chinese medicine composition sample 1# (treatment group, decoction, oral administration, 1 time in the morning and evening) and the gynecological climbing fern tablets (control group, 1 time 6 tablets, 1 day 3 times) as described in example 1. And (3) comprehensive curative effect comparison: 31 treatment groups, 8 clinical recovery cases, 19 obvious cases, 4 effective cases and 0 ineffective case, and the total effective rate is 100 percent (31/31); in 29 control groups, 0 clinical recovery cases, 6 significant cases, 19 effective cases and 5 ineffective cases are clinically cured, and the total effective rate is 82.8 percent (24/29). Therefore, the traditional Chinese medicine composition is superior to the gynecological climbing fern tablets (p is less than 0.01 or p is less than 0.05) in the aspects of symptom integration (shown in table 1), serum estrogen, progestogen and other indexes.
TABLE 1 grading of symptoms due to dampness, stasis, obstruction, cold-warm syndrome
TABLE 2 comparison of the improvement of symptom score between the treatment group of the Chinese medicinal composition of the present invention and the control group of pain-relieving and illness-eliminating capsules
Note: comparison before and after treatment of the same group: p <0.05, p < 0.01; comparison of Δ p <0.05, Δ p <0.01 before and after treatment in both groups
Example 6
60 rats are selected to be divided into a model blank control group, a model gynecological Qianjin tablet treatment group, a model traditional Chinese medicine composition treatment group, a model paniculate swallowwort root treatment group and a pseudo-operation blank control group for research, and the purpose is to explain the treatment effect and mechanism of the traditional Chinese medicine composition on the rat model with pelvic inflammatory disease. The method comprises the following steps: constructing a rat model of pelvic inflammatory disease, injecting hydrochloric acid and lipopolysaccharide into the upper genital tract, and then performing intragastric administration for 15 days by using the traditional Chinese medicine composition. Histological examination, immunohistochemical analysis, analgesic assay and ELISA examination were performed. As a result: the traditional Chinese medicine composition can obviously inhibit infiltration of neutrophilic granulocytes and lymphocytes of uterus of a rat with pelvic inflammatory disease; analgesic test shows that the traditional Chinese medicine composition can obviously inhibit the writhing frequency of a mouse on a hot plate and improve the pain threshold of the mouse; meanwhile, the traditional Chinese medicine composition can reduce the levels of serum interleukin-1 beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha), intercellular adhesion molecule-1 (ICAM-1) and Vascular Endothelial Growth Factor (VEGF).
As shown in fig. 1A and 1B, compared with the model blank control group, the gynecological climbing fern tablet, the traditional Chinese medicine composition of the invention and the paniculate swallowwort root single-medicine control group all significantly reduce inflammatory cells in the uterus (fig. 1A) and the fallopian tube (fig. 1B). As shown in fig. 1C and 1D, the semi-quantitative results show that compared with the model blank control group, the single medicine of the traditional Chinese medicine composition of the present invention, the single medicine of paniculate swallowwort root and the gynecological herba euphorbiae lathyris can both reduce the inflammatory cells in the uterus and the fallopian tube significantly, and the treatment group of the traditional Chinese medicine composition of the present invention is closer to the blank control group of the pseudo-operation (fig. 1C and 1D).
Meanwhile, compared with a model blank control group, the wriggle times of mice treated by indomethacin and the single medicine of the traditional Chinese medicine composition and the paniculate swallowwort root are both obviously reduced (p is less than 0.001), and the pain inhibition rate of the traditional Chinese medicine composition treatment group (41.8%) and the paniculate swallowwort root single medicine treatment group (36.3%) is lower than that of the indomethacin control group (53.9%). The specific results are shown in Table 3.
TABLE 3 analgesic Effect
| Group of | Number of painful torsions | Pain inhibition ratio (%) |
| Blank control group | 47.9±1.65 | — |
| Indometacin group | 21.8±1.91*** | 53.9±4.43 |
| Decoction group for removing stasis and calming the female | 27.6±0.99*** | 41.8±2.70 |
| Paniculate swallowwort root single-ingredient medicine | 30.3±1.10*** | 36.3±2.74 |
P <0.001vs. blank control group
In addition, in order to observe the change of inflammatory response, the serum IL-1. beta., TNF-. alpha., ICAM-1 and VEGF levels of the model group rats were measured by ELISA method, and the results are shown in FIG. 2. As can be seen from FIG. 2, compared with the sham-operated blank control group, the serum IL-1 beta, TNF-alpha, ICAM-1 and VEGF levels of the model group are all significantly increased, and the gynecological climbing fern tablets, the traditional Chinese medicine composition and the paniculate swallowwort root have obvious inhibition effects on the generation of the cytokines of the rats. These results show that after the model is made, rats all show inflammatory reaction, and the traditional Chinese medicine composition has anti-inflammatory effect. In addition, the traditional Chinese medicine composition also inhibits the cell adhesion and angiogenesis of the rat with the pelvic inflammatory disease.
In addition, as can be seen from fig. 3A and 3B, the ICAM-1 staining rate of rats in the uterus or the oviduct was lower in the single-drug treatment group of the traditional Chinese medicine composition and paniculate swallowwort compared with the model blank control group. As shown in FIGS. 3C and 3D, semi-quantitative analysis shows that the single medicine of the traditional Chinese medicine composition and the paniculate swallowwort root can obviously reduce the expression of ICAM-1.
Moreover, as can be seen from fig. 4, the VEGF level in the uterus or oviduct of the model blank control group is increased, but the VEGF level of the traditional Chinese medicine composition of the present invention and the single-herb cynanchum paniculatum treatment group is significantly decreased. It is worth noting that the traditional Chinese medicine composition of the invention completely reverses the increase of VEGF, but the paniculate swallowwort root in the formula can only partially reverse the increase of VEGF level, especially in uterus. This shows that other drugs in the Chinese medicinal composition of the invention also have strong anti-angiogenesis effect.
In conclusion, the traditional Chinese medicine composition for treating sequelae of pelvic inflammatory diseases has good effects of relieving pain, activating blood circulation, resisting inflammation and the like through the synergistic effect of the preferable components, and can achieve the effects of eliminating dampness and stasis and treating Kunzeiding. Therefore, the invention effectively overcomes various defects in the prior art and has high industrial utilization value.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.
Claims (10)
1. The traditional Chinese medicine composition comprises the following active ingredients in parts by weight:
10-14 parts of ground beetle;
10-14 parts of radix angelicae pubescentis;
10-14 parts of szechwan chinaberry fruit;
13-17 parts of paniculate swallowwort root.
2. The traditional Chinese medicine composition according to claim 1, wherein the effective components comprise the following components in parts by weight:
11-13 parts of Chinese polyphaga;
11-13 parts of pubescent angelica root;
11-13 parts of szechwan chinaberry fruit;
14-16 parts of paniculate swallowwort root.
3. A herbal extract prepared from the herbal composition of any one of claims 1-2.
4. The method for preparing a herbal extract of claim 3, wherein the herbal extracts are prepared by mixing the ingredients in a predetermined ratio, adding a solvent to the mixture, soaking the mixture in the solvent, decocting the mixture, and collecting the filtrate.
5. The method as claimed in claim 4, wherein the ratio of the mass g of the Chinese medicinal composition to the volume mL of the solvent is 43-59: 250-350.
6. The method for preparing Chinese medicinal extract according to claim 4, wherein the soaking time is 25-35 min.
7. The method for preparing Chinese medicinal extract as claimed in claim 4, wherein the decocting is boiling and then decocting.
8. The method for preparing a herbal extract as claimed in claim 7, wherein the boiling temperature is 95-105 deg.C; the decocting time is 20-30 min.
9. A pharmaceutical preparation comprising the Chinese medicinal composition according to any one of claims 1 to 2 or the Chinese medicinal extract according to claim 3, wherein the pharmaceutical preparation is selected from one of granules or oral liquid.
10. Use of a Chinese medicinal composition according to any one of claims 1-2, a Chinese medicinal extract according to claim 3, or a pharmaceutical preparation according to claim 9 in the preparation of a medicament for treating sequelae of pelvic inflammatory disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910248021.8A CN109893557B (en) | 2019-03-29 | 2019-03-29 | Traditional Chinese medicine composition for treating sequelae of pelvic inflammatory disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910248021.8A CN109893557B (en) | 2019-03-29 | 2019-03-29 | Traditional Chinese medicine composition for treating sequelae of pelvic inflammatory disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109893557A CN109893557A (en) | 2019-06-18 |
| CN109893557B true CN109893557B (en) | 2022-01-25 |
Family
ID=66954023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910248021.8A Active CN109893557B (en) | 2019-03-29 | 2019-03-29 | Traditional Chinese medicine composition for treating sequelae of pelvic inflammatory disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109893557B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1555862A (en) * | 2004-01-05 | 2004-12-22 | 吴长秀 | Chinese medicine for treating palvic infection |
| CN103566060A (en) * | 2012-07-23 | 2014-02-12 | 孙子云 | Traditional Chinese medicine enema agent for treating gynecologic inflammations |
| CN105250519A (en) * | 2015-10-19 | 2016-01-20 | 黄淮学院 | Traditional Chinese medicine composition for relieving sequelae of pelvic inflammatory disease and application of traditional Chinese medicine composition |
-
2019
- 2019-03-29 CN CN201910248021.8A patent/CN109893557B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1555862A (en) * | 2004-01-05 | 2004-12-22 | 吴长秀 | Chinese medicine for treating palvic infection |
| CN103566060A (en) * | 2012-07-23 | 2014-02-12 | 孙子云 | Traditional Chinese medicine enema agent for treating gynecologic inflammations |
| CN105250519A (en) * | 2015-10-19 | 2016-01-20 | 黄淮学院 | Traditional Chinese medicine composition for relieving sequelae of pelvic inflammatory disease and application of traditional Chinese medicine composition |
Non-Patent Citations (1)
| Title |
|---|
| Comparison of the Analgesic and Anti-Inflammatory Effects of Xiaoyuningkun Decoction with Cynanchum Paniculatum and Fukeqianjin in a Mouse Model of Pelvic Inflammatory Disease;Bixin Tang;《Med Sci Monit.》;20191130;第25卷;第9094-9102页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109893557A (en) | 2019-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104523865A (en) | Medicine for treating breast diseases | |
| CN103599472B (en) | A kind of Chinese medicine composition being used for the treatment of prostatic hyperplasia | |
| CN102973677B (en) | Traditional Chinese medicine for treating ovarian cyst | |
| CN104474473A (en) | Traditional Chinese medicine composition for treating gynecologic inflammation and preparation method thereof | |
| CN1325110C (en) | Medicated wine for treating traumatic injury | |
| CN109893557B (en) | Traditional Chinese medicine composition for treating sequelae of pelvic inflammatory disease | |
| CN103705632B (en) | The application of BUPIXIAO PIAN in preparation treatment penile induration disease drug | |
| CN104043089A (en) | Medical biological dressing suppository for treating hemorrhoid | |
| CN111729057A (en) | Traditional Chinese medicine composition for treating calculus | |
| CN100556434C (en) | Prostatitic medicine of a kind of treatment and preparation method thereof | |
| CN104474456A (en) | Traditional Chinese medicinal pill for treating hysteromyoma | |
| CN103520592B (en) | The Chinese medicine decoction for the treatment of gynecologic chronic pelvic pain | |
| CN115804805B (en) | Traditional Chinese medicine compound composition for treating ankylosing spondylitis and external medicine bag | |
| CN103520638B (en) | A kind of Traditional Chinese medicine compound composition for the treatment of prostate hyperplasia and preparation method thereof and application thereof | |
| CN103330793B (en) | Traditional Chinese medicine enema for treating chronic pelvic inflammatory disease | |
| CN110013525B (en) | Medicine for treating chronic epididymitis and preparation method | |
| CN110179893B (en) | Enema liquid of ten ingredients with ginseng and angelica and preparation process thereof | |
| CN102688456B (en) | Chinese medicinal composition for treating chronic prostatitis | |
| Liu et al. | Treatment of primary dysmenorrhea with herb-partitioned moxibustion plus ultra-short wave | |
| CN101618118B (en) | Application of Chinese medicinal composition in preparing medicament for treating cystitis | |
| CN105641586A (en) | Fengtongning preparation and preparation method thereof | |
| CN106421694A (en) | Externally used Chinese herba preparation for treating dysmenorrhea | |
| CN101757379A (en) | Traditional Chinese medicine formula for treating female pelvic inflammation | |
| CN105456648A (en) | Compound five-vine pain reliving paster | |
| CN104666824A (en) | Traditional Chinese medicinal composition for treating psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |